Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib with Reinduction Chemotherapy in Pediatric and Young Adult AML
NCT00666588Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2008
- Primary completion
- Dec 2012
- Modality
- Small Molecules, Modified Peptides
- Countries
- 3
01
Overview
Phase 2, open-label trial of bortezomib in acute myeloid leukemia (AML) (4 arms), sponsored by National Cancer Institute. Primary endpoints: Dose Limiting Toxicity and Overall Response Rate. Started Apr 2008; status: completed.
02
Drugs
bortezomib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00666588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00666588.